AK+ Guard software is aimed at identifying hyperkalaemia, a condition that can suddenly cause cardiac arrests. Credit: Jo Panuwat D / Shutterstock.

AccurKardia has gained the US Food and Drug Administration’s (FDA) breakthrough device designation for its AI-powered ‘AK+ Guard’ software, aimed at identifying hyperkalaemia, a condition that can suddenly cause cardiac arrests.

The software leverages ‘Lead I ECG’ data to provide timely alerts for this life-threatening condition that occurs due to high potassium levels in the blood.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Compatible with a variety of FDA-cleared consumer and clinical devices such as smartwatches, AK+ Guard facilitates continuous monitoring of hyperkalaemia in subjects, especially those with chronic kidney disease (CKD) or end-stage renal disease, allowing for early intervention outside clinical settings, the company noted.

The recent FDA Total Product Life Cycle Advisory Program (TAP) inclusion of AK+ Guard is set to expedite the regulatory process, ensuring quality device evaluations and quicker market access.

AccurKardia’s portfolio also includes the AK-AVS software, which screens for aortic valve stenosis (AVS) by analysing ECG data. This software is aimed at identifying patients who may require echocardiograms for a definitive diagnosis.

Last October, the company gained breakthrough designation from the FDA for AVS ECG-based AI screening software.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

AccurKardia CEO and co-founder Juan Jimenez said: “The two FDA actions supporting AK+ Guard mark another major milestone in AccurKardia’s journey towards achieving our mission to improve patient outcomes and save lives by transforming ECG into a broad biomarker.

“We believe the current standard of care for hyperkalaemia detection and monitoring is underserving patients, and we aim to deliver a speedier and more accessible pathway to detection and risk management that will make a meaningful impact on patient care.”

In the US, CKD affects an estimated 37 million individuals. A common complication of the illness is hyperkalaemia, which the company noted has been linked to a 16.6% increase in death rates.